Expert Consensus on Ion Channel Drugs for Chronic Pain Treatment in China
© 2024 Ma et al..
Ion channel drugs have been increasing used for chronic pain management with progress in the development of selective calcium channel modulators. Although ion channel drugs have been proven safe and effective in clinical practice, uncertainty remains regarding its use to treat chronic pain. To standardize the clinical practice of ion channel drug for the treatment of chronic pain, the National Health Commission Capacity Building and Continuing Education Center for Pain Diagnosis and Treatment Special Ability Training Project established an expert group to form an expert consensus on the use of ion channel drugs for the treatment of chronic pain after repeated discussions on existing medical evidence combined with the well clinical experience of experts. The consensus provided information on the mechanism of action of ion channel drugs and their recommendations, caution use, contraindications, and precautions for their use in special populations to support doctors in their clinical decision-making.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:17 |
|---|---|
| Enthalten in: |
Journal of pain research - 17(2024) vom: 07., Seite 953-963 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Ma, Ke [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Chronic pain |
|---|
| Anmerkungen: |
Date Revised 14.03.2024 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.2147/JPR.S445171 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM369665929 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM369665929 | ||
| 003 | DE-627 | ||
| 005 | 20240315000011.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240313s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2147/JPR.S445171 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1329.xml |
| 035 | |a (DE-627)NLM369665929 | ||
| 035 | |a (NLM)38476873 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Ma, Ke |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Expert Consensus on Ion Channel Drugs for Chronic Pain Treatment in China |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 14.03.2024 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a © 2024 Ma et al. | ||
| 520 | |a Ion channel drugs have been increasing used for chronic pain management with progress in the development of selective calcium channel modulators. Although ion channel drugs have been proven safe and effective in clinical practice, uncertainty remains regarding its use to treat chronic pain. To standardize the clinical practice of ion channel drug for the treatment of chronic pain, the National Health Commission Capacity Building and Continuing Education Center for Pain Diagnosis and Treatment Special Ability Training Project established an expert group to form an expert consensus on the use of ion channel drugs for the treatment of chronic pain after repeated discussions on existing medical evidence combined with the well clinical experience of experts. The consensus provided information on the mechanism of action of ion channel drugs and their recommendations, caution use, contraindications, and precautions for their use in special populations to support doctors in their clinical decision-making | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a chronic pain | |
| 650 | 4 | |a ion channel drugs | |
| 650 | 4 | |a voltage-gated calcium channels | |
| 650 | 4 | |a voltage-gated sodium channel | |
| 700 | 1 | |a Cheng, Zhixiang |e verfasserin |4 aut | |
| 700 | 1 | |a Jiang, Hao |e verfasserin |4 aut | |
| 700 | 1 | |a Lin, Zhangya |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Chuansheng |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Xianguo |e verfasserin |4 aut | |
| 700 | 1 | |a Lu, Lijuan |e verfasserin |4 aut | |
| 700 | 1 | |a Lu, Yan |e verfasserin |4 aut | |
| 700 | 1 | |a Tao, Wei |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Suoliang |e verfasserin |4 aut | |
| 700 | 1 | |a Yang, Xiaoqiu |e verfasserin |4 aut | |
| 700 | 1 | |a Yi, Qishan |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Xiaomei |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Ying |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Yanqing |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of pain research |d 2008 |g 17(2024) vom: 07., Seite 953-963 |w (DE-627)NLM204715385 |x 1178-7090 |7 nnns |
| 773 | 1 | 8 | |g volume:17 |g year:2024 |g day:07 |g pages:953-963 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.2147/JPR.S445171 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 17 |j 2024 |b 07 |h 953-963 | ||